Compare Stocks: EXEL, NTRA, RVMD, and ALNY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$266.11 +0.6%	$259.76	$197.81 ▼ $495.55	$35.61B	0.31	1.46 million shs	1.43 million shs
EXEL Exelixis	$59.01 -0.2%	$54.98	$33.76 ▼ $59.72	$14.62B	0.42	2.66 million shs	1.58 million shs
NTRA Natera	$328.18 +0.2%	$291.29	$157.43 ▼ $343.18	$47.30B	1.54	1.35 million shs	968,061 shs
RVMD Revolution Medicines	$210.02 -0.4%	$196.37	$39.17 ▼ $224.31	$45.02B	1.4	2.97 million shs	884,506 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-1.08%	+11.81%	+20.79%	-12.72%	-40.88%
EXEL Exelixis	+1.03%	+7.00%	+5.59%	+12.20%	+59.98%
NTRA Natera	+0.77%	-3.26%	+19.07%	+52.19%	+95.59%
RVMD Revolution Medicines	+0.78%	-4.65%	+9.00%	+41.31%	+430.22%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$266.11 +0.6%	$259.76	$197.81 ▼ $495.55	$35.61B	0.31	1.46 million shs	1.43 million shs
EXEL Exelixis	$59.01 -0.2%	$54.98	$33.76 ▼ $59.72	$14.62B	0.42	2.66 million shs	1.58 million shs
NTRA Natera	$328.18 +0.2%	$291.29	$157.43 ▼ $343.18	$47.30B	1.54	1.35 million shs	968,061 shs
RVMD Revolution Medicines	$210.02 -0.4%	$196.37	$39.17 ▼ $224.31	$45.02B	1.4	2.97 million shs	884,506 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-1.08%	+11.81%	+20.79%	-12.72%	-40.88%
EXEL Exelixis	+1.03%	+7.00%	+5.59%	+12.20%	+59.98%
NTRA Natera	+0.77%	-3.26%	+19.07%	+52.19%	+95.59%
RVMD Revolution Medicines	+0.78%	-4.65%	+9.00%	+41.31%	+430.22%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.88	Moderate Buy	$386.14	46.74% Upside
EXEL Exelixis	2.35	Hold	$50.07	-15.11% Downside
NTRA Natera	2.82	Moderate Buy	$319.38	-2.11% Downside
RVMD Revolution Medicines	2.95	Moderate Buy	$200.74	-3.92% Downside

Current Analyst Ratings Breakdown

Latest EXEL, NTRA, RVMD, and ALNY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	ALNY Alnylam Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$455.00
9/1/2026	EXEL Exelixis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/31/2026	ALNY Alnylam Pharmaceuticals	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/31/2026	ALNY Alnylam Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/31/2026	ALNY Alnylam Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/31/2026	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$240.00 ➝ $275.00
8/28/2026	RVMD Revolution Medicines	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$220.00 ➝ $265.00
8/28/2026	RVMD Revolution Medicines	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$240.00 ➝ $275.00
8/27/2026	RVMD Revolution Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$203.00 ➝ $251.00
8/27/2026	RVMD Revolution Medicines	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$248.00
8/27/2026	RVMD Revolution Medicines	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$230.00 ➝ $260.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$4.80B	7.33	$2.75 per share	95.63	$10.12 per share	26.00
EXEL Exelixis	$2.32B	6.30	$3.05 per share	19.33	$7.44 per share	7.93
NTRA Natera	$2.31B	20.39	N/A	N/A	$12.64 per share	25.81
RVMD Revolution Medicines	$11.58M	3,867.15	N/A	N/A	$12.16 per share	17.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$5.38	48.91	27.27	N/A	15.26%	84.93%	14.30%	10/29/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.18	18.55	15.90	1.74	35.33%	42.17%	31.76%	11/3/2026 (Estimated)
NTRA Natera	-$208.16M	-$1.36	N/A	32,624.50	N/A	-7.11%	-11.38%	-7.87%	11/5/2026 (Estimated)
RVMD Revolution Medicines	-$1.13B	-$8.82	N/A	N/A	N/A	N/A	-88.20%	-57.85%	11/4/2026 (Estimated)

Latest EXEL, NTRA, RVMD, and ALNY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	NTRA Natera	-$0.4939	-$0.47	+$0.0239	-$0.47	$661.24 million	$752.75 million
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million
8/5/2026	Q2 2026	RVMD Revolution Medicines	-$2.04	-$3.06	-$1.02	-$3.06	$1.77 million	N/A
7/30/2026	Q2 2026	ALNY Alnylam Pharmaceuticals	$1.63	$1.84	+$0.21	$1.21	$1.32 billion	$1.29 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
NTRA Natera	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.75	3.05	2.99
EXEL Exelixis	N/A	3.46	3.38
NTRA Natera	N/A	3.00	2.85
RVMD Revolution Medicines	0.40	11.38	11.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
EXEL Exelixis	85.27%
NTRA Natera	99.90%
RVMD Revolution Medicines	94.34%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
EXEL Exelixis	2.60%
NTRA Natera	5.05%
RVMD Revolution Medicines	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.66 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable
NTRA Natera	6,140	144.14 million	136.87 million	Optionable
RVMD Revolution Medicines	250	214.34 million	198.05 million	Optionable

EXEL, NTRA, RVMD, and ALNY Headlines

Recent News About These Companies

Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?

September 4 at 12:37 PM | zacks.com

Revolution Medicines Got Its Breakthrough—What Moves It Next?

...

September 4 at 10:20 AM | marketbeat.com

Lorence Kim Sells 56,000 Shares of Revolution Medicines (NASDAQ:RVMD) Stock

September 4 at 4:41 AM | americanbankingnews.com

Corient Private Wealth LP Acquires New Stake in Revolution Medicines, Inc. $RVMD

September 4 at 3:51 AM | marketbeat.com

J.P. Morgan Sticks to Their Buy Rating for Revolution Medicines (RVMD)

September 3 at 10:44 PM | theglobeandmail.com

Revolution Medicines Highlights NEJM Publication Of RASONQUE Lung Cancer Data

September 3 at 7:43 AM | rttnews.com

Revolution Medicines (NASDAQ:RVMD) Director Lorence Kim Sells 56,000 Shares

September 3 at 6:06 AM | insidertrades.com

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

September 2 at 5:50 PM | globenewswire.com

Insider Selling: Revolution Medicines (NASDAQ:RVMD) Director Sells $11,381,440.00 in Stock

September 2 at 5:07 PM | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Revolution Medicines (RVMD)

September 2 at 10:17 AM | theglobeandmail.com

Revolution Medicines, Inc. $RVMD Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

September 2 at 5:04 AM | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

September 2 at 1:13 AM | americanbankingnews.com

Revolution Medicines: Benefit Vs. Reality Compared To Peer Therapeutics

September 1 at 10:39 AM | seekingalpha.com

Needham & Company LLC Raises Revolution Medicines (NASDAQ:RVMD) Price Target to $275.00

August 31, 2026 | marketbeat.com

Moore Capital Management LP Has $15.30 Million Holdings in Revolution Medicines, Inc. $RVMD

August 31, 2026 | marketbeat.com

Public Employees Retirement System of Ohio Buys Shares of 77,402 Revolution Medicines, Inc. $RVMD

August 31, 2026 | marketbeat.com

HC Wainwright Issues Pessimistic Outlook for RVMD Earnings

August 31, 2026 | americanbankingnews.com

HC Wainwright Has Pessimistic Outlook of RVMD Q3 Earnings

August 31, 2026 | marketbeat.com

Patients with the deadliest cancer finally have something that works

August 30, 2026 | malaysia.news.yahoo.com

Revolution Medicines, Inc. $RVMD Shares Sold by Jasper Ridge Partners L.P.

August 30, 2026 | marketbeat.com

Revolution Medicines, Inc. $RVMD Shares Sold by Wellington Management Group LLP

August 30, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EXEL, NTRA, RVMD, and ALNY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$266.11 +1.61 (+0.61%)

As of 04:00 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Exelixis NASDAQ:EXEL

$59.01 -0.12 (-0.20%)

As of 04:00 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Natera NASDAQ:NTRA

$328.18 +0.51 (+0.16%)

As of 04:00 PM Eastern

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Revolution Medicines NASDAQ:RVMD

$210.02 -0.85 (-0.40%)

As of 04:00 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EXEL, NTRA, RVMD, and ALNY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EXEL, NTRA, RVMD, and ALNY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EXEL, NTRA, RVMD, and ALNY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EXEL, NTRA, RVMD, and ALNY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Exelixis NASDAQ:EXEL

Natera NASDAQ:NTRA

Revolution Medicines NASDAQ:RVMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EXEL, NTRA, RVMD, and ALNY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EXEL, NTRA, RVMD, and ALNY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EXEL, NTRA, RVMD, and ALNY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EXEL, NTRA, RVMD, and ALNY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Exelixis NASDAQ:EXEL

Natera NASDAQ:NTRA

Revolution Medicines NASDAQ:RVMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools